What forze armate does

Stabilimento Chimico Farmaceutico Militare Firenze (SCFM) is an Italian state-owned military pharmaceutical production facility founded in 1853, operating under Agenzia Industrie Difesa (AID) — a Public Law Entity supervised by the Italian Minister of Defense. It occupies approximately 55,000 m² in the Rifredi district of Florence and functions as the only Italian state hub that integrates industrial pharmaceutical manufacturing (GMP and GACP certified), strategic procurement of complex medical systems, and emergency logistics. Its primary customer is the Italian Armed Forces, with secondary civil use cases spanning orphan drug distribution, public health emergency response, and international humanitarian projects.

SCFM's core product portfolio is multi-disciplinary. In pharmaceuticals and biotechnology, it produces orphan drugs not available on the global market (Mexiletine, Tiopronin, D-penicillamine), operates the only national center for medical cannabis cultivation and distribution (FM1 and FM2 varieties), deploys a sixth-generation robotic aseptic filling system ("Azzurra") for injectables and vaccines, and manufactures CBRN antidotes and decontamination kits. In strategic procurement, it supplies modular field hospitals with HEPA-filtered HVAC, transportable CBRN decontamination modules, mobile ICU ISO containers, combat medical kits, and individual first-aid kits. Additional lines cover nutraceuticals (ITAVIS brand), functional cosmetics, herbal liqueurs, and biocide repellents (Permethrin). Recent R&D efforts include next-generation antidote programs (DANTE, MANDRA, ARES), cannabis phytocomplex research (FITNESS), and the MIUR-recognized Centro di Ricerca per la Farmaceutica e Chimica Applicata.

The business model is government procurement rather than commercial sales: revenue is generated through centralized purchasing for the Ministry of Defense and Ministry of Health, while rare-disease medications are distributed via the dedicated Portale Farmaci platform. Pricing is not publicly disclosed. The facility participates in EU-level initiatives such as the EU4HEALTH Joint Action on Strategic Stockpiles (2025–2028) and contributes to international humanitarian projects, including the Odessa neonatal ward reconstruction (2025–2026) under the Italian Agency for Development Cooperation.

Name

forze armate

Legal name

Stabilimento Chimico Farmaceutico Militare Firenze - Agenzia Industrie Difesa

Website

https://farmaceuticomilitare.it

Company type

Private

Founded year

1853

Operating status

Operating

Headcount range

251–500 employees

Short description

SCFM Firenze is an Italian state-owned military pharmaceutical facility under Agenzia Industrie Difesa, producing orphan drugs, medical cannabis, CBRN antidotes, and mobile medical infrastructure for the Italian Armed Forces, rare disease patients, and public health emergencies.

Ownership category

akta.pro rank

Product category

Military Pharmaceutical Manufacturing

NAICS

Fire Protection (92216)

SIC

Services-Commercial Physical & Biological Research (8731), Industrial & Commercial Fans & Blowers & Air Purifing Equip (3564)

akta.pro primary industry

Security, Sabotage & All-Hazards Preparedness (Including Natural Hazards) (EUAHALAL)

akta.pro secondary industries

Biohazard Spill Response & Decontamination Services (BPALAGAH), Process Safety & Major Hazard Risk Management (PSM) (BPAHAJAE)

Keywords

• Military pharmaceuticals
• Orphan drug production
• Medical cannabis cultivation
• CBRN countermeasures
• Mobile field hospitals

Headquarters

HQ city

Firenze

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Government Pharmaceutical Production & Procurement: Production of ethical pharmaceuticals including orphan drugs (Mexiletine, Tiopronin, D-penicillamine), medical cannabis, antidotes, and CBRN countermeasures for Italian Armed Forces and national strategic stockpiles. Operates as a procurement center for complex medical systems under Agenzia Industrie Difesa.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

Stabilimento Chimico Farmaceutico Militare (SCFM) di Firenze is a state-owned military pharmaceutical production facility that manufactures ethical pharmaceuticals including orphan drugs for rare diseases, medical cannabis (FM1/FM2 varieties), CBRN antidotes, and combat medical kits for the Italian Armed Forces. It also operates as a strategic procurement hub through Agenzia Industrie Difesa, supplying modular field hospitals, mobile ICU units, and CBRN decontamination modules for defense and emergency response operations.

Product overview

The Stabilimento Chimico Farmaceutico Militare (SCFM) is a multi-product pharmaceutical and defense manufacturing facility operating under Agenzia Industrie Difesa. It functions as a unified industrial site combining domestic production capabilities with strategic procurement for complex health systems. The product portfolio encompasses: (1) Pharmaceutical & Biotechnological products including Orphan Drugs/Rare Disease medications (Mexiletina, Tiopronina, D-penicillina), Medical Cannabis (FM1 and FM2 varieties), the Azzurra aseptic filling robotic system, and CBRN antidotes; (2) Nutraceutical, Cosmetic and Life-Support products under the ITAVIS brand plus functional cosmetics and herbal liqueurs; (3) Biocides including Permethrin-based repellents; (4) Strategic procurement solutions including Modular Field Hospitals, CBRN Decontamination Modules, Mobile ICU Units; and (5) Integrated Medical Kits including Individual/Unit Kits, Stop Shock Combat Medicals Kits, CBRN Response Kits, and Enterprise/Civilian First Aid Kits compliant with Italian workplace safety regulations.

Differentiator

Problem solved

Functional benefit

Products and services

• Orphan Drugs for Rare Diseases Ethical production of life-saving molecules (Mexiletine/Mexiletina, Tiopronin/Tiopronina, D-penicillamine/D-penicillina) for rare diseases that are not available on the global market, produced under Legge 175/2021 and the National Plan for Rare Diseases.
• Medical Cannabis FM1 and FM2 Only national center for cultivation, transformation, and pharmaceutical distribution of medical cannabis (FM1 and FM2 varieties), including standardized inflorescences and oil extracts. Includes research on new phytocomplexes for neurological applications and pain therapy (Progetto FITNESS).
• CBRN Antidotes and Countermeasures

Quantifiable outcome

• Produced orphan drugs (Mexiletine, Tiopronin, D-penicillamine) for life-threatening rare diseases unavailable globally
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• European Commission / EU4HEALTH ProgrammecoreStrategic or Co-development Partner · 1 January 2025SCFM participates in EU4HEALTH JA Stockpile (Joint Action on Comprehensive and Sustainable Strategic Stockpiles of Medical Countermeasures) for 2025-2028, managing Workpackages 6 and 7 on behalf of the Ministry of Health. This represents a significant European-level strategic partnership for medical countermeasure stockpiling.
• Agenzia Italiana per la Cooperazione allo Sviluppo (MAECI)coreStrategic or Co-development Partner · 1 January 2025SCFM is contributing to the reconstruction of the Neonatal Department in Odessa, Ukraine (2025-2026) through the Italian Agency for Development Cooperation, representing international humanitarian assistance in healthcare reconstruction.
• Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR)minorStrategic or Co-development Partner · 1 January 2025MIUR recognized the Centro di Ricerca per la Farmaceutica e Chimica Applicata (Research Center for Applied Pharmaceuticals and Chemistry) in 2025, establishing an academic-research partnership for pharmaceutical advancement.
• Ministero della Salute (Ministry of Health)coreStrategic or Co-development Partner · 1 January 2014Joint ministerial directive (Health and Defense ministries, 2014) established therapeutic cannabis experimentation, with SCFM designated as sole national producer. SCFM operates under Law 175/2021 for orphan drugs and the National Plan for Rare Diseases.

Scale indicators4 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• Laboratoire de Production et de Contrôle (LPC) - French Defence Health Service: French military pharmaceutical production facility operated under the French Defence Health Service (Service de Santé des Armées). Produces pharmaceutical products for French Armed Forces including antidotes, vaccines, and emergency medical countermeasures — directly comparable as a European state-owned military pharmaceutical production entity serving national defense needs.
• Stabilimento Militare Munizionamento Terrestre (AID Baiano di Spoleto): Another AID-managed state military production facility producing ground munitions. Shares the same institutional structure, parent entity (Agenzia Industrie Difesa), government-only revenue model, and Italian Ministry of Defense oversight as SCFM.
• Avon Protection: UK-based global manufacturer of CBRN respiratory protection equipment and military survivability solutions. Comparable in CBRN defense product focus and military customer base, though Avon specializes in protective equipment rather than pharmaceutical antidotes and decontamination kits.
• Stabilimento Militare Pirotecnico (AID Capua): A sister production facility under Agenzia Industrie Difesa producing military pyrotechnics and explosives. Directly comparable as a state-owned defense industrial entity under the same parent organization (AID) with similar governance structure, government-only customer base, and specialized defense production mandate.
• Bundeswehr Institute of Pharmacology and Toxicology: Germany's military pharmacology and toxicology research institute, operated under the Bundeswehr. Functions as the German counterpart for military pharmaceutical R&D, CBRN defense research, and pharmaceutical support to armed forces — directly comparable in mission, customer base (national military), and CBRN defense focus.

Broad incumbents

• Jazz Pharmaceuticals: Specialty pharmaceutical company with significant cannabis-based medicine portfolio (legacy GW Pharmaceuticals) including Sativex and Epidiolex. Comparable in pharmaceutical-grade cannabis production for medical use, but operates as a global commercial entity with FDA-approved cannabis-derived therapies.
• Swedish Orphan Biovitrum (Sobi): Swedish-headquartered specialty biopharmaceutical company focused exclusively on rare diseases and orphan drug development. Comparable in orphan drug production focus and rare disease patient access mission, but operates as a publicly-traded commercial enterprise with broader geographic reach.
• Recordati Rare Diseases: Italian specialty pharmaceutical company with a dedicated rare diseases division focused on orphan drug development and distribution. Comparable in orphan drug therapeutic focus and Italian pharmaceutical market presence, but operates as a commercial entity serving global markets rather than as a state monopoly supplier.
• Drägerwerk (Dräger Safety): German global leader in safety and medical technology with a dedicated CBRN and emergency response product portfolio including respiratory protection, detection systems, and decontamination equipment. Comparable in CBRN defense mission and emergency response positioning, but operates as a broad commercial safety equipment manufacturer.

Emerging players

• Tilray Brands: Global medical cannabis producer with operations across multiple countries, supplying pharmaceutical-grade cannabis for medical use. Comparable in medical cannabis cultivation and pharmaceutical-grade production, but operates as a commercial company in regulated private markets rather than as a state monopoly producer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCcM2K-ggtirIxqKsKW5M7dA/f
• Facebookfacebook.com/AgenziaIndustrieDifesa
• LinkedInlinkedin.com/company/forze-armate
• Instagraminstagram.com/agenziaindustriedifesa?igshid=YmMyMTA2M2Y=

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about forze armate